FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR?T CELLS AND ENROLLED IN DESCAR?T REGISTRY, A FRENCH REAL?LIFE DATABASE FOR CAR?T CELLS IN HEMATOLOGIC MALIGNANCIES

Background: DESCAR-T is the French national registry for patients treated with commercial CAR-T cells (DLBCL and ALL). has been designed by LYSA/LYSARC aims to collect real-life data. was approved authorities in 2019 reference reimbursement health authorities. Data (patients’ characteristics, safety, efficacy long-term outcome…) from time of medical decision treat up 15 years after infusion are registered DESCAR-T. Several complementary registries also linked database (immune-monitoring, blood tumor biobanking -CeVi-CART, imagery platform). We present first analyses regarding DLBCL patients' characteristics outcome Methods: All were eligible study. gave informent consent befor registration. Results: To date (Jan 2021), 14 out 24 accredited centers have (other being opened). The patient December 2019. At analysis, 537 registered. product ordered 517 whom 463 infused. registration DESCAR-T, median age 63.0 (range, 53-70), 40.6% > 65yrs 3.5% 75yrs. Lymphoma subtypes (91%), PMBL (3%), high-grade B-cell lymphoma (2%). Among (n = 517), 313 (60.5%) male, 76 (14.7%) had a PS?2, 377 (72.9%) an advanced disease (stage III or IV), 330 (63.8%) elevated LDH. Median number prior lines treatment 3 2 – 3) 21% previously transplanted. order 50 days [range, 43-60]. leukapheresis 41.1 36-48). Overall, 65% received Axi-cel 35% Tisa-acel. Response available 419 infused patients. Best ORR 70.2% (65.5% - 74.5%). D30 cell infusion, 157 (38%) achieved CR 112 (27%) PR. who at D30, 96 (61%) remained D90. follow-up calculated 7.4 months 5.8-7.9) 6m 5.5-6.2] infusion. OS 12.7m 10.6-NA]. Summary/Conclusion: This analysis seems confirm real life. Updated results will be presented meeting. 13 months. demontrates that therapy become key R/R DLBCL. In 2021, extended MCL multiple myeloma. EA submitted EHA 2021. Keywords: Aggressive non-Hodgkin lymphoma, Cellular therapies Conflicts interests pertinent abstract S. Le Gouill Consultant advisory role: Gilead; Novartis